September 29, 2019 10:31 AM EDT

Merck's top cancer team basks in the warm light of positive Keytruda data from a landmark study for hard-to-treat breast cancer

John Carroll

Editor & Founder

BARCELONA — While Bristol-Myers Squibb execs spent much of the weekend in Barcelona trying to explain the more positive aspects of recent data on Opdivo …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck's top cancer team basks in the warm light of positive Keytruda data from a landmark study for hard-to-treat breast cancer

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Mer­ck­'s top can­cer team basks in the warm light of pos­i­tive Keytru­da da­ta from a land­mark study for hard-to-treat breast can­cer

Editor & Founder

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Merck's top cancer team basks in the warm light of positive Keytruda data from a landmark study for hard-to-treat breast cancer